The invention provides an artificial hybrid antibody comprising two different heavy/light chain pairs and two different binding sites, or active fragment thereof, wherein a first heavy/light chain pair binds beta-amyloid. The invention also provides a composition comprising the artificial hybrid antibody or active fragment thereof, and the composition for use in a method of treating or alleviating one or more effects of amyloidosis. The invention further provides a cell comprising two different nucleic acid molecules encoding a humanized antibody or epitope-binding fragment thereof that binds to beta-amyloid and method of producing a humanized antibody or epitope-binding fragment thereof that binds to beta-amyloid.
